Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Diagnosis of Constitutional Mismatch Repair-deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.

Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, Guilloux A, Chalastanis A, Lafitte P, Coulet F, Buisine MP, Ilencikova D, Ruiz-Ponte C, Kinzel M, Grandjouan S, Brems H, Lejeune S, Blanché H, Wang Q, Caron O, Cabaret O, Svrcek M, Vidaud D, Parfait B, Verloes A, Knappe UJ, Soubrier F, Mortemousque I, Leis A, Auclair-Perrossier J, Frébourg T, Fléjou JF, Entz-Werle N, Leclerc J, Malka D, Cohen-Haguenauer O, Goldberg Y, Gerdes AM, Fedhila F, Mathieu-Dramard M, Hamelin R, Wafaa B, Gauthier-Villars M, Bourdeaut F, Sheridan E, Vasen H, Brugières L, Wimmer K, Muleris M, Duval A; European Consortium “Care for CMMRD” (C4CMMRD).

Gastroenterology. 2015 Jun 24. pii: S0016-5085(15)00872-0. doi: 10.1053/j.gastro.2015.06.013. [Epub ahead of print]

PMID:
26116798
2.

Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation.

Benusiglio PR, Colas C, Rouleau E, Uhrhammer N, Romero P, Remenieras A, Moretta J, Wang Q, De Pauw A, Buecher B, Stoppa-Lyonnet D, Mouret-Fourme E, Noguès C, Di Maria M, Tlemsani C, Warcoin M, Grandjouan S, Malka D, Caron O, Blayau M.

J Med Genet. 2015 Aug;52(8):563-5. doi: 10.1136/jmedgenet-2015-103153. Epub 2015 May 29. No abstract available.

PMID:
26025002
3.

Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art.

de Baere T, Tselikas L, Pearson E, Yevitch S, Boige V, Malka D, Ducreux M, Goere D, Elias D, Nguyen F, Deschamps F.

Diagn Interv Imaging. 2015 Jun;96(6):647-54. doi: 10.1016/j.diii.2015.04.004. Epub 2015 May 16.

PMID:
25985998
4.

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk.

Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T.

Eur J Hum Genet. 2015 Apr 15. doi: 10.1038/ejhg.2015.72. [Epub ahead of print]

PMID:
25873010
5.

An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report.

Daou B, Zanello M, Varlet P, Brugieres L, Jabbour P, Caron O, Lavoine N, Dhermain F, Willekens C, Beuvon F, Malka D, Lechapt-Zalcmann E, Abi Lahoud G.

Neurosurgery. 2015 Jul;77(1):E145-52. doi: 10.1227/NEU.0000000000000754.

PMID:
25850602
6.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E.

Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075. Epub 2015 Mar 13.

PMID:
25770151
7.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Leclercq J, Juzyna B, Ezra P, Lemanski C, Deutsch E.

Radiother Oncol. 2015 Mar;114(3):415-6. doi: 10.1016/j.radonc.2015.02.008. Epub 2015 Mar 11. No abstract available.

PMID:
25769380
8.

Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.

Colussi O, Voron T, Pozet A, Hammel P, Sauvanet A, Bachet JB, Vaillant JC, Rougier P, Nordlinger B, Berger A, Coriat R, Dousset B, Malka D, André T, Paye F, Aparicio T, Locher C, Cojean Zeleck D, Tchinou L, Bonnetain F, Taieb J.

Eur J Surg Oncol. 2015 Apr;41(4):520-6. doi: 10.1016/j.ejso.2015.01.010. Epub 2015 Jan 24.

PMID:
25680954
9.

Effect of spatial coherence on damage occurrence in multimode optical fibers.

Herzog A, Malka D, Zalevsky Z, Ishaaya AA.

Opt Lett. 2015 Feb 1;40(3):415-8. doi: 10.1364/OL.40.000415.

PMID:
25680061
10.

Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study.

Rahmi G, Lecomte T, Malka D, Maniere T, Le Rhun M, Guimbaud R, Lapalus MG, Le Sidaner A, Moussata D, Caron O, Barbieux JP, Gaudric M, Coron E, Barange K, Ponchon T, Sautereau D, Samaha E, Saurin JC, Chaussade S, Laurent-Puig P, Chatellier G, Cellier C.

Am J Gastroenterol. 2015 Feb;110(2):288-98. doi: 10.1038/ajg.2014.423. Epub 2015 Jan 20.

PMID:
25601014
11.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V.

Eur J Cancer. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

PMID:
25559615
12.

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.

Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, Elias D, Bouché O, Ducreux M.

Eur J Cancer. 2015 Jan;51(2):166-76. doi: 10.1016/j.ejca.2014.10.023. Epub 2014 Nov 24.

PMID:
25465185
13.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Asnacios A, Manet-Lacombe S, Fein F, Dubreuil O, Landi B, Zaanan A, Bonnetain F, Taïeb J.

Eur J Cancer. 2014 Dec;50(18):3116-24. doi: 10.1016/j.ejca.2014.09.015. Epub 2014 Oct 17.

PMID:
25454414
14.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L.

Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Review.

PMID:
25256896
15.

Prospects for diode-pumped alkali-atom-based hollow-core photonic-crystal fiber lasers.

Sintov Y, Malka D, Zalevsky Z.

Opt Lett. 2014 Aug 15;39(16):4655-8. doi: 10.1364/OL.39.004655.

PMID:
25121841
16.

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardière C, Manfredi S, Solub D, Lécaille C, Thirot Bidault A, Carbonnel F, Taieb J.

Ann Surg Oncol. 2015 Jan;22(1):295-301. doi: 10.1245/s10434-014-3898-9. Epub 2014 Jul 19.

PMID:
25037971
17.

[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].

Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F.

Bull Cancer. 2014 Jun;101(6):647-52. doi: 10.1684/bdc.2014.1986. French.

PMID:
24977454
18.

Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor.

Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, Boige V, Malka D, Leboulleux S, Ducreux M, Baudin E, Deschamps F.

Cardiovasc Intervent Radiol. 2015 Apr;38(2):372-80. doi: 10.1007/s00270-014-0914-1. Epub 2014 May 30.

PMID:
24873919
19.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

PMID:
24852116
20.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.

Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V.

Invest New Drugs. 2014 Oct;32(5):1028-35. doi: 10.1007/s10637-014-0100-y. Epub 2014 Apr 22.

PMID:
24748335
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk